Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Terminated 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2

Conditions

Vaginal Atrophy 1Urogenital Abnormalities 1Urinary Tract Infections 1Dysuria 1Dyspareunia 1Breast Neoplasms 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Replens × Clear all
NCT01984138 2026-01-28

REVIVE

The Methodist Hospital Research Institute

Phase 2 Active not recruiting
33 enrolled
Breast

Breast Neoplasms

NCT04493333 2024-11-27

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors

University of Arkansas

Phase 2 Terminated
8 enrolled 11 charts
Breast

Vaginal Atrophy

NCT03185169 2018-07-26

GSM

Alta Bates Summit Medical Center

Phase EARLY_PHASE1 Terminated
14 enrolled

Dyspareunia, Urinary Tract Infections, Urogenital Abnormalities, Dysuria

Data powered by HemOnc (CC BY 4.0) Colophon âš¡